Eosinophilic Esophagitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Eosinophilic Esophagitis - Pipeline Review, H2 2018’, provides an overview of the Eosinophilic Esophagitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis

- The report reviews pipeline therapeutics for Eosinophilic Esophagitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Eosinophilic Esophagitis therapeutics and enlists all their major and minor projects

- The report assesses Eosinophilic Esophagitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adare Pharmaceuticals Inc

Calypso Biotech SA

Celgene Corp

DBV Technologies SA

Dr. Falk Pharma GmbH

GlaxoSmithKline Plc

Humanigen Inc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc ...

Adare Pharmaceuticals Inc

Calypso Biotech SA

Celgene Corp

DBV Technologies SA

Dr. Falk Pharma GmbH

GlaxoSmithKline Plc

Humanigen Inc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Eosinophilic Esophagitis - Overview

Eosinophilic Esophagitis - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Eosinophilic Esophagitis - Overview

Eosinophilic Esophagitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Eosinophilic Esophagitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Eosinophilic Esophagitis - Companies Involved in Therapeutics Development

Adare Pharmaceuticals Inc

Calypso Biotech SA

Celgene Corp

DBV Technologies SA

Dr. Falk Pharma GmbH

GlaxoSmithKline Plc

Humanigen Inc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Shire Plc

Eosinophilic Esophagitis - Drug Profiles

BPRX-060216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budesonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CALY-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HGEN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Gene Therapy for Asthma and Eosinophilic Esophagitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPC-4046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viaskin Milk - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Eosinophilic Esophagitis - Dormant Projects

Eosinophilic Esophagitis - Product Development Milestones

Featured News & Press Releases

Nov 09, 2017: New medicine for rare inflammatory condition of the esophagus

Oct 16, 2017: Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses

Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy

Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions

Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin® Milk in Milk-Induced Eosinophilic Esophagitis in Children

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis

Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients

Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis

May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children

Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis

May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis

May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H2 2018

Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2018

Eosinophilic Esophagitis - Pipeline by Celgene Corp, H2 2018

Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H2 2018

Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2018

Eosinophilic Esophagitis - Pipeline by GlaxoSmithKline Plc, H2 2018

Eosinophilic Esophagitis - Pipeline by Humanigen Inc, H2 2018

Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2018

Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2018

Eosinophilic Esophagitis - Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports